Vimarsana
Biggest News Aggregation in the World

Page 16 - Practice Research News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Practice Research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Practice Research Today - Breaking & Trending Today

MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab - Vimarsana News

MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab

frontMIND Study Evaluating Tafasitamab Combination as a  First-line Treatment for Diffuse Large B-Cell Lymphoma PLANEGG/MUNICH, Germany and WILMINGTON, Del., USA - May 11, 2021 - MorphoSys AG (FSE:MOR; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that the first patient has been dosed in the pivotal Phase 3 frontMIND study evaluating tafasitamab and lenalidomide in addition to rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) compared to R-CHOP alone as first-line treatment for high-intermediate and high-risk patients with untreated diffuse large B-cell ly...

MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line Treatment for Diffuse Large B-Cell Lymphoma - Vimarsana News

MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line Treatment for Diffuse Large B-Cell Lymphoma

MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line Treatment for Diffuse Large B-Cell Lymphoma ACCESSWIRE 12 May 2021, 06:05 GMT+10 PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / May 11, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that the first patient has been dosed in the pivotal Phase 3 frontMIND study evaluating tafasitamab and lenalidomide in addition to rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) compared to R-CHOP alone as fi...

MorphoSys AG: MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line Treatment for Diffuse Large B-Cell Lymphoma - Vimarsana News

MorphoSys AG: MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line Treatment for Diffuse Large B-Cell Lymphoma

MorphoSys AG: MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line Treatment for Diffuse Large B-Cell Lymphoma The frontMIND (NCT04824092) trial is a randomized, double-blind, placebo-controlled, global Phase 3 clinical study in previously untreated high-intermediate and high-risk DLBCL patients that is conducted in partnership with the German Lymphoma Association (GLA), the Italian Lymphoma study group and the US Oncology Network. The study aims to enroll approximately 880 DLBCL patients to receive either tafasitamab...

Fintech disruption trends: a changing payment landscape on the horizon - Vimarsana News

Fintech disruption trends: a changing payment landscape on the horizon

3 March 2021 Fintech disruption trends: a changing payment landscape on the horizon From the rise of software-based payment technology and cross-border e-commerce to an increase in Fraud-as-a-Service, this article explores 2021's main fintech disruption trends What are the main fintech disruption trends impacting the banking sector? From embedded finance to the demand for software-based payment technology, cross-border e-commerce and the the rise of Fraud-as-a-Service, this article explores the main fintech disruption trends the financial serv...

Insurtech disruption trends: is traditional insurance broken? - Vimarsana News

Insurtech disruption trends: is traditional insurance broken?

What are the main Insurtech disruption trends? In this article four leading insurtechs discuss the decline of traditional insurance